mRNA Therapeutics CDMO Market Report 2026

The mrna therapeutics cdmo market size has grown rapidly in recent years. It will grow from $4.74 billion in 2025 to $5.31 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to limited availability of specialized mrna cdmo services, reliance on in-house pharmaceutical manufacturing, growing infectious disease outbreaks, adoption of early-stage analytical testing, expansion of academic and research collaborations.

The mrna therapeutics cdmo market size is expected to see rapid growth in the next few years. It will grow to $8.26 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to rising investment in mrna therapeutics pipelines, technological advancements in plasmid dna and mrna synthesis, growth of cancer immunotherapy and protein replacement therapies, increasing demand for fill-finish services, expansion of partnerships between biotechs and cdmos. Major trends in the forecast period include rising demand for outsourced mrna development and manufacturing, increasing focus on lipid nanoparticle (lnp) formulation technologies, expansion of viral vaccine and cancer immunotherapy pipelines, enhanced regulatory compliance and quality assurance measures, growing adoption of analytical and bioanalytical laboratory services.

The growing burden of chronic and infectious diseases is expected to drive growth in the mRNA therapeutics CDMO market in the coming years. Chronic and infectious diseases include long-term health conditions such as diabetes, cardiovascular disorders, and asthma, as well as illnesses caused by pathogenic microorganisms like viruses, bacteria, and parasites, which can spread directly or indirectly among individuals. The prevalence of these diseases is rising due to aging populations, which are more vulnerable to both long-term illnesses and infections. mRNA therapeutics CDMOs help address these conditions by providing end-to-end development and manufacturing services that accelerate the delivery of targeted, personalized mRNA therapies to patients. For example, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from around 7.5 million in 2022, highlighting the escalating global burden of infectious diseases. This indicates that the increasing prevalence of chronic and infectious diseases is fueling growth in the mRNA therapeutics CDMO market.

Key companies in the mRNA therapeutics CDMO market are focusing on innovative solutions, such as in situ nanomedicine vaccines, to improve the effectiveness and precision of mRNA-based vaccines through targeted immune stimulation. An in situ nanomedicine vaccine is a next-generation mRNA therapeutic designed to produce nanomedicines within the patient’s body, enabling targeted delivery and customized immune activation through engineered transgene expression. For instance, in January 2025, Esphera SynBio Inc., a Canada-based biotechnology company, launched a project supported by the CQDM Quantum Leap program. The initiative seeks to enhance first-generation lipid nanoparticle/mRNA (LNP/mRNA) vaccines by incorporating proprietary transgene designs that induce in vivo production of immunostimulatory nanomedicines. This technology allows precise antigen delivery and tailored immune responses, representing a potential breakthrough in vaccine development.

In September 2024, Agilent Technologies Inc., a U.S.-based medical equipment company, acquired BIOVECTRA for $0.925 billion. The acquisition aims to expand Agilent’s CDMO capabilities into high-growth modalities, including mRNA therapeutics, by leveraging BIOVECTRA’s expertise in biologics and advanced pharmaceutical manufacturing. BIOVECTRA is a Canada-based contract development and manufacturing organization specializing in mRNA therapeutics and other modalities.

Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.

North America was the largest region in the mRNA therapeutics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mrna therapeutics cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the mRNA therapeutics CDMO market by increasing costs for imported raw materials, specialized reagents, and advanced laboratory equipment required for mRNA synthesis and LNP formulation. Segments such as plasmid DNA manufacturing, fill-finish services, and viral vaccine production are most affected, particularly in regions like Asia-Pacific including China and India. While tariffs create short-term cost pressures and supply chain challenges, they also encourage domestic production, local sourcing of materials, and innovation in manufacturing efficiency.

The mrna therapeutics cdmo market research report is one of a series of new reports that provides mrna therapeutics cdmo market statistics, including mrna therapeutics cdmo industry global market size, regional shares, competitors with a mrna therapeutics cdmo market share, detailed mrna therapeutics cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the mrna therapeutics cdmo industry. This mrna therapeutics cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An mRNA therapeutics CDMO, or messenger ribonucleic acid therapeutics contract development and manufacturing organization, is a specialized third-party entity that offers comprehensive support for the research, development, and large-scale production of mRNA-based therapeutic agents under contractual agreements with pharmaceutical or biotechnology companies. These organizations play a key role in accelerating time-to-market, maintaining regulatory compliance, and providing flexible manufacturing capacity for mRNA therapeutic pipelines.

The main types of services offered by mRNA therapeutics CDMOs include development services, manufacturing services, and laboratory services. Development services encompass end-to-end support for the design, optimization, and scale-up of mRNA therapeutics, including synthesis, formulation, analytical development, and process development tailored to client-specific products. These therapeutics are applied across indications such as infectious diseases, metabolic and genetic disorders, and cardiovascular and cerebrovascular conditions, and are used in applications including viral vaccines, protein replacement therapies, and cancer immunotherapies. The end users include pharmaceutical companies, biotechnology firms, academic institutions, and research organizations.

The mRNA therapeutics CDMO market consists of revenues earned by entities by providing services such as supply chain management, cold chain logistics, quality assurance auditing, clinical trial material preparation, batch release testing, serialization, and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The mRNA therapeutics CDMO market also includes sales of products such as lipid excipients, nucleotide reagents, capping analogs, custom RNA oligonucleotides, and modified nucleosides. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.